Video: “Management of Advanced Prostate Cancer”

July 2022 Awareness Night Dr. Di (Maria) Jiang, MD, Msc, FRCPC Staff Oncologist, Genitourinary Group Princess Margaret Cancer Centre, UHN Asst Prof., Clinician Investigator, Dept of Medicine, U. of Toronto   CLICK ON THE ARROW TO START THE VIDEO The Complete Presentation time is 1:33:48 Disclaimer:  The contents of this video is solely for the purposes of education and information and does not constitute personal diagnostic advice or personal medical advice.   

Video: “Advanced Prostate Cancer”

January 2021 Awareness Night Treatment of Advanced Prostate Cancer: From A(palutamide) to Z(ytiga(tm))  Dr. Urban Emmenegger, MD Medical Oncologist, Odette Cancer Centre (Div. of Medical Oncology) and Sunnybrook Research Institute (Biological Sciences Platform) Assistant Professor, Dept. of Medicine, U. of Toronto Associate Member, Inst. of Medical Science, U. of Toronto CLICK ON THE ARROW TO START THE VIDEO The Complete Presentation time is 2:15:05 <

A Phase III clinical trial of high-intensity exercise in the management of advanced prostate cancer

According to a news release just issued by Queen’s University, Belfast, a group of  150 researchers around the world is coming together to expand enrollment and access to the Australian INTERVAL trial into a global trial to test whether serious exercise should be prescribed as part of the treatment for men with advanced prostate cancer. Read the article.

Adding chemotherapy to hormone therapy added 14 months to patients’ lives in study

Chemotherapy at the start of hormone therapy can extend the lives of men with prostate cancer that has spread beyond the gland, a new study finds. Over nearly 29 months of follow-up, men with advanced prostate cancer who received the combination therapy lived almost 14 months longer than men who received only hormone therapy (58 months versus 44 months), researchers said. Read the article.

Increased Risk of Diabetes among Patients Receiving Primary Androgen Deprivation Therapy for Clinically Localized Prostate Cancer.

Androgen deprivation therapy (ADT) may increase diabetes risk. As benefits of primary ADT (PADT) for localized PCa are controversial, and most PCa survivors are of advanced age with comorbidities, it is important to determine if PADT increases diabetes risk and what are the susceptibility factors. Read the article.  (Free UroToday login required.)

UroToday Introduces Advanced Prostate Cancer Treatment Video Channel

UroToday has expanded its video-on-demand content in the UrologyTUBE™ with a new video channel featuring multi-media lectures focusing on treatment of men with advanced prostate cancer. The new channel specifically focuses on androgen deprivation treatment (hormone treatment) as the backbone of advanced prostate cancer treatment. View the channel.  (Free UroToday login required.)  

Bipolar Androgen Therapy

Research hope for prostate cancer Pouring petrol on the fire can potentially reverse resistance to hormone treatments for prostate cancer, new research suggests. The counter-intuitive strategy called bipolar androgen therapy (BAT) involves boosting levels of the male hormone testosterone, which normally stimulates prostate cancer growth. In a small pilot study, scientists found that alternating high and low testosterone levels caused seven of 16 patients with resistant prostate cancer to go into remission. Read the article.

Scroll to Top